



Global Health
L i m i t e d

13th February, 2023

Ref:- **GHL/2022-23/EXCH/022**

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)

Dear Sir(s),

We would like to inform you that the Board of Directors of the Company at its meeting held today i.e. *Monday, February 13, 2023*, has *inter alia*, approved:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Nine months ended December 31, 2022 (Results); and
2. The binding term sheet for a new hospital at Indore on Operation & Management basis. The details as required under Regulation 30 are in Exhibit.

The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiook & Co LLP, Chartered Accountants thereon, are enclosed herewith pursuant to Regulation 33 of Listing Regulations.

The meeting of the Board of Directors commenced at 3:30 P.M. and concluded at 6: 20 P.M.




This is for your information and records.

Thanking You,
For Global Health Limited

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035



Encl: a/a




Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

S. No.	Particulars of Events	Information
1.	Name(s) of parties with whom the agreement is entered	M/s Elinquisite Real Estate Private Limited, incorporated under the laws of India having its registered office at and corporate at Hakim Singh, Punjab Automobiles, Plot No.A-7, Priha Plaza Transport Nagar, Jaipur- Rajasthan (Lessor)
2.	Purpose of entering into the agreement	Under the arrangement i.e. binding term sheet (subject to successful and satisfactory due diligence report), the lessor will be responsible for construction of hospital building as per Company's specification to accommodate approximately 300 beds within a period of 3-4 years. Post receipt of building completion certificate, the same shall be leased to the Company for a period of 29 years. All medical equipment shall be installed by the Company.
3.	Shareholding, if any, in the entity with whom the agreement is executed;	NIL
4.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	There will not be any special rights for appointment of director, issuance of shares or other restrictions on Company. However, there is a lock-in of 15 years for the Company and 29 years on lessor for lease.
5.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship;	No
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	No



Global Health L i m i t e d

7.	In case of issuance of shares to the parties, details of issue price, class of shares issued;	Not Applicable
8.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc;	NIL
9.	in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof	Not Applicable



Walker Chandiook & Co LLP

Walker Chandiook & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II
Gurugram – 122 002
India

T +91 124 4628099
F +91 124 4628001

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited (formerly Global Health Private Limited) pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited (formerly Global Health Private Limited)

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Global Health Limited (formerly Global Health Private Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 31 December 2022 and the consolidated year to date results for the period 1 April 2022 to 31 December 2022, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.



Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-11 Connaught Circus, New Delhi, 110001, India

Walker Chandiook & Co LLP

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited (formerly Global Health Private Limited) pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Rajni Mundra

Rajni Mundra

Partner

Membership No. 058644



UDIN: 23058644BGXZNU4107

Place: Gurugram

Date: 13 February 2023

Walker ChandioK &Co LLP

Annexure I to the Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited (formerly Global Health Private Limited) pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1

List of entities included in the Statement

S. No.	Name	Relationship with the Holding Company
1	Medanta Holdings Private Limited	Wholly owned subsidiary
2	Global Health Patliputra Private Limited	Wholly owned subsidiary
3	GHL Pharma and Diagnostic Private Limited	Wholly owned subsidiary [With effect from 29 June 2022]



Global Health Limited (*formerly known as Global Health Private Limited*)
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India
CIN:L85110DL2004PLC128319

Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: <https://www.medanta.org>
Statement of consolidated unaudited financial results for the quarter and nine months ended 31 December 2022

(In Rs. Lakhs)

S No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 December 2022	30 September 2022	31 December 2021	31 December 2022	31 December 2021	31 March 2022
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
	Income						
I	Revenue from operations	69,432.21	67,905.55	58,317.78	1,99,082.65	1,64,621.45	2,16,729.79
II	Other income	1,190.39	1,550.98	1,022.53	3,650.84	2,645.44	3,851.89
	Total income	70,622.60	69,456.53	59,340.31	2,02,733.49	1,67,266.89	2,20,581.68
	III Expenses						
	Cost of materials consumed	14,384.67	14,160.20	13,326.37	42,051.81	39,001.16	50,822.08
	Purchases of stock-in-trade	1,360.12	1,244.91	1,073.45	3,955.02	2,846.26	3,752.72
	Changes in inventories of stock-in-trade	51.02	132.47	(112.65)	44.32	(268.00)	(282.11)
	Employee benefits expense	15,960.56	16,028.13	14,544.35	47,542.92	42,222.45	56,796.11
	Finance costs	2,067.40	1,823.29	1,783.95	5,743.90	5,136.65	7,948.60
	Depreciation and amortisation expense	3,875.37	3,713.24	3,308.62	11,196.48	9,494.39	12,971.29
	Impairment losses on financial assets	284.07	140.91	172.87	476.72	454.61	333.58
	Retainers and consultants fee	8,467.91	8,361.68	6,362.18	24,204.79	16,569.78	23,509.73
	Other expenses	12,926.54	12,178.79	9,388.99	35,896.41	26,678.12	36,673.97
	Total expenses	59,377.66	57,783.62	49,848.13	1,71,112.37	1,42,135.42	1,92,525.97
	IV Profit before tax	11,244.94	11,672.91	9,492.18	31,621.12	25,131.47	28,055.71
	Tax expenses						
	Current tax (including earlier years)	2,555.98	2,545.85	2,340.41	7,507.23	7,043.86	8,566.21
	Deferred tax expense/(credit)	627.58	559.07	158.44	1,613.23	222.75	(130.29)
	V Profit after tax	8,061.38	8,567.99	6,993.33	22,500.66	17,864.86	19,619.79
	Other comprehensive income						
	A (i) Items that will not be reclassified to statement of profit or loss	33.46	(24.83)	58.92	77.58	91.18	(297.08)
	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(7.32)	6.47	(14.94)	(18.00)	(23.41)	74.69
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income-tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	VI Total other comprehensive income	26.14	(18.36)	43.98	59.58	67.77	(222.39)
	VII Total comprehensive income	8,087.52	8,549.63	7,037.31	22,560.24	17,932.63	19,397.40
	Profit after tax attributable to:						
	(i) Owners of the Holding Company	8,061.38	8,567.99	6,993.33	22,500.66	17,864.86	19,619.79
	(ii) Non-controlling interests	-	-	-	-	-	-
	Other comprehensive income attributable to:						
	(i) Owners of the Holding Company	26.14	(18.36)	43.98	59.58	67.77	(222.39)
	(ii) Non-controlling interests	-	-	-	-	-	-
	Total comprehensive income attributable to:						
	(i) Owners of the Holding Company	8,087.52	8,549.63	7,037.31	22,560.24	17,932.63	19,397.40
	(ii) Non-controlling interests	-	-	-	-	-	-
VIII	Paid-up equity share capital (face value of Rs. 2 each)	5,363.70	5,066.08	5,064.48	5,363.70	5,064.48	5,064.48
IX	Reserves (other equity)						1,56,536.30
	X Earnings per share (face value of Rs. 2 each) (not annualised except for the year ended 31 March 2022)						
	Basic (Rs. per share)	3.08	3.38	2.76	8.79	7.09	7.78
	Diluted (Rs. per share)	3.08	3.38	2.76	8.78	7.08	7.77

See accompanying notes to the consolidated financial results



(This space has been intentionally left blank)



**SIGNED FOR
IDENTIFICATION
PURPOSE ONLY**

Notes to the consolidated unaudited financial results:

- 1 The above consolidated financial results of Global Health Limited (formerly Global Health Private Limited) ('the Holding Company') and its wholly owned subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') for the quarter and nine months ended 31 December 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 February 2023 and a limited review of the same has been carried out by the statutory auditors.
- 2 These consolidated financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The chief operating decision maker (CODM) examines the Group's performance from a service perspective and has identified the Healthcare services as a single business segment. The Group is operating in India which constitutes a single geographical segment.
- 4 During the nine months period ended 31 December 2022, the Holding Company has incorporated a wholly owned subsidiary namely, GHL Pharma and Diagnostic Private Limited. Additionally, the Holding Company has further infused equity amounting to Rs. 2,000 lakhs and Rs. 1,001 lakhs in its wholly owned subsidiaries, namely, Global Health Patliputra Private Limited and GHL Pharma and Diagnostic Private Limited, respectively.
- 5 During the quarter ended 31 December 2022, the Holding Company has made an Initial Public Offer (IPO) of 6,56,41,952 equity shares of face value of Rs. 2 each at a price of Rs. 336 per equity share (including share premium of Rs. 334 per equity share) aggregating to Rs. 2,20,556.96 lakhs. This comprises of fresh issue of 1,48,80,952 equity shares aggregating to Rs. 50,000 lakhs and an offer for sale of 5,07,61,000 equity shares aggregating to Rs. 1,70,556.96 lakhs. The equity shares of the Holding Company got listed with BSE Limited and National Stock Exchange of India Limited on 16 November 2022.

The utilisation of the net initial public offer proceeds is summarised below:

Object of the issue	Utilisation planned*	Total utilised upto 31 December 2022	Amount pending for utilisation as 31 Decemeber 2022
Investment in the form of debt, equity or repayment/prepayment of the borrowings in full or part in wholly owned subsidiaries Global Health Patliputra Private Limited and Medanta Holdings Private Limited	37,500.00	-	37,500.00
General corporate purposes	10,170.10	-	10,170.10
Total	47,670.10	-	47,670.10

* Net of share issue expense of Rs 2,329.90 lakhs

The above mentioned unutilised proceeds have been temporarily invested in deposits with banks.

- 6 During the nine months period ended 31 December 2022, the Holding Company has allotted 80,000 equity shares under the Holding Company's Employee Stock Options Schemes on exercise of vested options by eligible employees.
- 7 Previous period figures have been regrouped/reclassified to conform to the current period's classification.



For and on behalf of the Board of Directos of Global Health Limited

Dr. Naresh Trehan
 Chairman and Managing Director

Place : Gurugram
 Date : 13 February 2023

**SIGNED FOR
 IDENTIFICATION
 PURPOSE ONLY**

Walker Chandiook & Co LLP

Walker Chandiook & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II
Gurugram – 122 002
India

T +91 124 4628099
F +91 124 4628001

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited (formerly Global Health Private Limited) pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited (formerly Global Health Private Limited)

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited (formerly Global Health Private Limited) ('the Company') for the quarter ended 31 December 2022 and the year to date results for the period 1 April 2022 to 31 December 2022, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

Walker Chandiook & Co LLP

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited (formerly Global Health Private Limited) pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Rajni *Mundra*

Rajni Mundra

Partner

Membership No. 058644



UDIN: 23058644BGXZNT2801

Place: Gurugram

Date: 13 February 2023

Global Health Limited (formerly known as Global Health Private Limited)
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corporate Office: Medanta – The Medicity, Sector – 38, Gurugram, Haryana - 122001, India
CIN:L85110DL2004PLC128319

Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: <https://www.medanta.org>
Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31 December 2022

(In Rs. Lakhs)

S No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 December 2022	30 September 2022	31 December 2021	31 December 2022	31 December 2021	31 March 2022
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
	Income						
I	Revenue from operations	48,978.60	49,408.02	46,711.84	1,45,653.63	1,35,388.80	1,76,495.77
II	Other income	1,252.29	1,317.93	764.36	3,358.08	2,288.45	3,503.88
	Total income	50,230.89	50,725.95	47,476.20	1,49,011.71	1,37,677.25	1,79,999.65
	Expenses						
III	Cost of materials consumed	10,634.67	10,510.27	10,738.98	31,762.99	32,647.48	42,191.19
	Purchases of stock-in-trade	815.21	771.98	807.63	2,530.82	2,181.03	2,931.38
	Changes in inventories of stock-in-trade	95.40	139.48	(71.77)	149.51	(198.81)	(278.54)
	Employee benefits expense	13,360.63	13,485.23	12,625.11	40,035.65	36,979.91	49,465.70
	Finance costs	649.22	664.11	697.99	1,978.24	2,108.98	2,758.28
	Depreciation and amortisation expense	2,161.56	2,227.43	2,215.85	6,573.44	6,517.18	8,717.31
	Impairment losses on financial assets	275.12	140.92	164.28	467.77	434.29	309.77
	Retainers and consultants fee	4,503.04	4,720.58	3,919.77	13,424.28	11,190.42	15,444.50
	Other expenses	9,746.67	9,324.86	7,394.13	27,337.89	21,287.30	28,877.32
	Total expenses	42,241.52	41,984.86	38,491.97	1,24,260.59	1,13,147.78	1,50,416.91
IV	Profit before tax	7,989.37	8,741.09	8,984.23	24,751.12	24,529.47	29,582.74
	Tax expenses						
	Current tax (including earlier years)	2,555.98	2,545.85	2,340.41	7,507.23	7,043.86	8,566.21
	Deferred tax credit	(443.87)	(336.94)	(171.34)	(985.09)	(582.19)	(861.87)
V	Profit after tax	5,877.26	6,532.18	6,815.16	18,228.98	18,067.80	21,878.40
VI	Other comprehensive income						
	A (i) Items that will not be reclassified to statement of profit or loss	21.04	(27.12)	51.30	57.70	83.63	(314.39)
	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(5.29)	6.82	(12.91)	(14.52)	(21.05)	79.13
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income-tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income	15.75	(20.30)	38.39	43.18	62.58	(235.26)
VII	Total comprehensive income	5,893.01	6,511.88	6,853.55	18,272.16	18,130.38	21,643.14
VIII	Paid-up equity share capital (face value of Rs. 2 each)	5,363.70	5,066.08	5,064.48	5,363.70	5,064.48	5,064.48
IX	Reserves (other equity)						1,68,910.84
X	Earnings per share (face value of Rs. 2 each) (no: annualised except for the year ended 31 March 2022)						
	Basic (Rs. per share)	2.25	2.58	2.69	7.12	7.17	8.68
	Diluted (Rs. per share)	2.25	2.58	2.68	7.11	7.16	8.66

See accompanying notes to the standalone financial results



(This space has been intentionally left blank)

**SIGNED FOR
IDENTIFICATION
PURPOSE ONLY**

Global Health Limited (formerly known as Global Health Private Limited)
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corporate Office: Medanta – The Medicity, Sector – 38, Gurugram, Haryana - 122001, India
CIN:L85110DL2004PLC128319
Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org

Notes to the standalone unaudited financial results:

- 1 The above standalone financial results for the quarter and nine months period ended 31 December 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 February 2023 and a limited review of the same has been carried out by the statutory auditors.
- 2 These standalone financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The chief operating decision maker (CODM) examines the Company's performance from a service perspective and has identified the Healthcare services as single business segment. The Company is operating in India which constitutes a single geographical segment.
- 4 During the nine months period ended 31 December 2022, the company has incorporated a wholly owned subsidiary namely, GHL Pharma and Diagnostic Private Limited. Additionally, the Company has infused equity amounting to Rs. 2,000 lakhs and Rs. 1,001 lakhs in its wholly owned subsidiaries, namely, Global Health Patliputra Private Limited and GHL Pharma and Diagnostic Private Limited, respectively.
- 5 During the quarter ended 31 December 2022, the Company has completed its Initial Public Offer ('IPO') of 6,56,41,952 equity shares of face value of Rs. 2 each for cash at a price of Rs. 336 per equity share (including a share premium of Rs. 334 per equity share) aggregating to Rs. 2,20,556.96 lakhs. This comprises of fresh issue of 1,48,80,952 equity shares aggregating up to Rs. 50,000 lakhs ('fresh issue') and an offer for sale of 5,07,61,000 equity shares aggregating to Rs. 1,70,556.96 lakhs. The equity shares of the Company got listed with BSE Limited and National Stock Exchange of India Limited on 16 November 2022.

The utilisation of the initial public offer proceeds is summarised below:

Object of the issue as per prospectus	Utilisation planned as per prospectus*	(In Rs. Lakhs)	
		Total utilised upto 31 December 2022	Amount pending for utilisation as 31 Decemeber 2022
Investment in the form of debt, equity or repayment/prepayment of the borrowings in full or part in wholly owned subsidiaries Global Health Patliputra Private Limited and Medanta Holdings Private Limited	37,500.00	-	37,500.00
General corporate purposes	10,170.10	-	10,170.10

* Net of share issue expense of Rs 2,329.90 lakhs

The above mentioned unutilised proceeds have been temporarily invested in deposits with banks.

- 6 During the nine months period ended 31 December 2022, the Company has allotted 80,000 equity shares under the Company's Employee Stock Options Schemes on exercise of vested options by eligible employees.
- 7 Previous period figures have been regrouped/reclassified to conform to the current period's classification.



For and on behalf of the Board of Directos of Global Health Limited

Dr. Naresh Trehan
 Chairman and Managing Director

Place : Gurugram
 Date : 13 February 2023

**SIGNED FOR
 IDENTIFICATION
 PURPOSE ONLY**